On Friday, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) opened lower -4.48% from the last session, before settling in for the closing price of $2.01. Price fluctuations for IRWD have ranged from $1.59 to $15.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1.05%. Company’s average yearly earnings per share was noted 101.20% at the time writing. With a float of $155.16 million, this company’s outstanding shares have now reached $160.02 million.
Let’s determine the extent of company efficiency that accounts for 267 employees. In terms of profitability, gross margin is 99.6%, operating margin of 28.68%, and the pretax margin is 18.91%.
Ironwood Pharmaceuticals Inc (IRWD) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Ironwood Pharmaceuticals Inc is 3.03%, while institutional ownership is 102.71%. The most recent insider transaction that took place on Feb 10 ’25, was worth 244,753. In this transaction Chief Executive Officer of this company sold 139,064 shares at a rate of $1.76, taking the stock ownership to the 1,160,634 shares. Before that another transaction happened on Feb 10 ’25, when Company’s Principal Accounting Officer sold 12,048 for $1.76, making the entire transaction worth $21,204. This insider now owns 279,655 shares in total.
Ironwood Pharmaceuticals Inc (IRWD) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 101.20% per share during the next fiscal year.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Trading Performance Indicators
Check out the current performance indicators for Ironwood Pharmaceuticals Inc (IRWD). In the past quarter, the stock posted a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.81. Likewise, its price to free cash flow for the trailing twelve months is 2.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.02, a number that is poised to hit 0.08 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Ironwood Pharmaceuticals Inc (IRWD)
Looking closely at Ironwood Pharmaceuticals Inc (NASDAQ: IRWD), its last 5-days average volume was 4.01 million, which is a jump from its year-to-date volume of 3.81 million. As of the previous 9 days, the stock’s Stochastic %D was 51.10%. Additionally, its Average True Range was 0.29.
During the past 100 days, Ironwood Pharmaceuticals Inc’s (IRWD) raw stochastic average was set at 9.33%, which indicates a significant decrease from 13.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 208.84% in the past 14 days, which was higher than the 108.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.4733, while its 200-day Moving Average is $4.8832. However, in the short run, Ironwood Pharmaceuticals Inc’s stock first resistance to watch stands at $2.0633. Second resistance stands at $2.2067. The third major resistance level sits at $2.2933. If the price goes on to break the first support level at $1.8333, it is likely to go to the next support level at $1.7467. Should the price break the second support level, the third support level stands at $1.6033.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Key Stats
There are currently 160,028K shares outstanding in the company with a market cap of 307.26 million. Presently, the company’s annual sales total 442,740 K according to its annual income of -1,002 M. Last quarter, the company’s sales amounted to 91,590 K and its income totaled 3,650 K.
